Press release - 26/03/2019 EUR 3 million in series A for the growth and development of Cytena GmbH The High-Tech Gründerfonds (HTGF) and two private investors are convinced of the importance of single-cell isolation for the production of biopharmaceuticals and for genetic analysis in research and diagnostics. EUR 3 million will be invested in the further development of the technology, the expansion of the sales organization and in opening up further applications for Cytena’s single-cell printers.https://www.gesundheitsindustrie-bw.de/en/article/press-release/eur-3-million-in-series-a-for-the-growth-and-development-of-cytena-gmbh
Article - 17/10/2018 Biologicals are becoming increasingly important to Boehringer Ingelheim Biopharmaceuticals are playing an increasingly important role in Boehringer Ingelheim’s development pipeline. Visible evidence of this is the company’s Biologicals Development Centre (BDC) that is currently being constructed in Boehringer Ingelheim’s Biberach plant and will bring the company’s process development under one roof by early 2020. Walter Pytlik from BIOPRO talked with Dr. Ing. Ralf Schumacher about the new centre.https://www.gesundheitsindustrie-bw.de/en/article/news/biologicals-are-becoming-increasingly-important-to-boehringer-ingelheim
Press release - 27/09/2018 The healthcare industry – the innovation driver of the 21st century: opportunities and challenges BIOPRO Baden-Württemberg’s new industry report entitled "The Healthcare Industry 2018: Facts and Figures for Baden-Württemberg" has just been published in both German and English. The topic neatly dovetails with the state’s political activities. An evaluation of the region carried out on behalf of the Baden-Württemberg government has clearly recognised the importance of the healthcare sector as a driver of innovation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-healthcare-industry-the-innovation-driver-of-the-21st-century
Press release - 27/08/2018 Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales.https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-announces-collaboration-with-genentech-to-develop-novel-nk-cell-engager-based-immunotherapeutics-for-multiple-cancer-tar
Article - 02/06/2017 SÜDPACK: a great example of biotech as a cross-sectoral technology SÜDPACK Verpackungen is a qualified supplier of plastic films to the biopharmaceutical industry. The company is the leading European manufacturer of packaging products for the food industry and also offers its expertise to the biopharmaceutical industry. In 2011, SÜDPACK created an exclusive cooperation partnership with Sartorius Stedim Biotech, a global technology provider for the pharmaceutical biotech industry, which has now been extended…https://www.gesundheitsindustrie-bw.de/en/article/news/suedpack-a-great-example-of-biotech-as-a-cross-sectoral-technology
Article - 24/05/2017 Ralf Reski: from moss to humans Prof. Dr. Ralf Reski conducts basic research at the University of Freiburg. But this is not all the well-known plant biotechnologist does. He also wants his ideas to become concrete products. This is why he established Greenovation Biotech GmbH, a company which produces novel drugs in mosses. The company’s first moss-produced drug candidate – Moss-aGal – a recombinant form of human α-galactosidase, is now being tested in a phase I clinical trial.…https://www.gesundheitsindustrie-bw.de/en/article/news/ralf-reski-from-moss-to-humans
Article - 23/02/2017 Rentschler places formulation on biopharmaceuticals production agenda with LEUKOCARE alliance On February 2, 2017, Rentschler Biotechnologie and LEUKOCARE announced a strategic alliance in which LEUKOCARE will become the exclusive formulation developer for the Laupheim-based contract manufacturer. Rentschler will acquire a 10% stake in LEUKOCARE, a biotech company established in 2003 and headquartered in Martinsried. On behalf of BIOPRO, Walter Pytlik spoke with the two CEOs, Rentschler’s Dr. Frank Mathias and LEUKOCARE’s Michael Scholl…https://www.gesundheitsindustrie-bw.de/en/article/news/rentschler-places-formulation-on-biopharmaceuticals-production-agenda-with-leukocare-alliance
Article - 16/06/2016 Microfluidic biofermenter mimics plant tissue It is estimated that as many as one million secondary plant metabolites can be used as medical agents. Plants produce these compounds to aid their growth and development as well as to discourage herbivores from eating them. However, it is still very difficult, or even impossible, to produce secondary plant metabolites industrially. Researchers from the Karlsruhe Institute of Technology (KIT) are now developing a microfluidic bioreactor to make…https://www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-biofermenter-mimics-plant-tissue
Press release - 07/04/2016 Speed dating for Pharmaceutical Process Technology – a business flirt at Bosch The speed dating format is no longer just a popular and simple dating method for lonely hearts, but has also become a rewarding way for establishing new business contacts and connections quickly and efficiently. BIOPRO Baden-Württemberg chose speed networking, as speed dating is called in the corporate world, for its recent Meet & Match event on pharmaceutical process technology, which took place on 15th March 2016 with the support of Bosch…https://www.gesundheitsindustrie-bw.de/en/article/press-release/speed-dating-for-pharmaceutical-process-technology-a-business-flirt-at-bosch
Article - 25/01/2016 And yet another biological from Biberach Boehringer Ingelheim is an important contract manufacturer of biopharmaceuticals that also produces proprietary drugs. We spoke with Dr. Joanne van Ryn, a Canadian pharmacologist who has been doing research at Boehringer Ingelheim’s company site in Biberach for over 20 years. Her research focuses on thrombosis, haemostasis and coagulation. She is involved in the scientific monitoring of dabigatran (Pradaxa), an oral anticoagulant that, in 2008,…https://www.gesundheitsindustrie-bw.de/en/article/news/and-yet-another-biological-from-biberach
Press release - 16/11/2015 The Baden-Württemberg healthcare industry – a strong economic power (Stuttgart – 16th November 2015) BIOPRO Baden-Württemberg has just published its latest analysis of the Baden-Württemberg healthcare industry including comprehensive facts and figures. Baden-Württemberg continues to be one of the top locations for medical technology, pharma and biotechnology in Germany. https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-baden-wuerttemberg-healthcare-industry-a-strong-economic-power
Overview Red biotechnology The latest articles, press releases and dossiers on red biotechnology in Baden-Württemberghttps://www.gesundheitsindustrie-bw.de/en/article/biotech
Overview Pharmaceutics The latest articles, press releases and dossiers on pharmaceutics in Baden-Württemberghttps://www.gesundheitsindustrie-bw.de/en/article/pharma
Article - 02/02/2015 Rentschler Biotechnologie invests in new production plant The Laupheim-based contract manufacturer Rentschler Biotechnologie GmbH is greatly expanding its production capacities. The company is investing €24 million in the construction of two 3,000 litre stainless steel bioreactors, which should be operational in early 2017 and will more than double the production capacities for cell culture-derived proteins. Rentschler also announced recently that it was adding a new 2,000 litre single-use bioreactor…https://www.gesundheitsindustrie-bw.de/en/article/news/rentschler-biotechnologie-invests-in-new-production-plant
Article - 31/01/2014 Experience report: internship at Boehringer Ingelheim in Shanghai A scholarship from the Baden-Württemberg Ministry of Science, Research and the Arts enabled Henrik Baran to do an internship at Boehringer Ingelheim Pharma GmbH and Co. KG in Shanghai. From March to August 2013, Henrik worked in the company's Global Biopharma Engineering & Technology department where he was involved in cleanroom planning. He was also project coordinator in charge of redeveloping company premises. Here he summarises his…https://www.gesundheitsindustrie-bw.de/en/article/news/experience-report-internship-at-boehringer-ingelheim-in-shanghai
Article - 06/05/2013 HeLa, a human bauplan in the Petri dish Scientists from EMBL have recently sequenced the genome of HeLa cells, which are the world’s most commonly used human cell line. They found that the HeLa genome and that of normal human cells reveal striking differences, caused by chromothripsis and other aberrations. Some evolutionary researchers believe that HeLa cells are developing a new human bauplan as they adapt to cultivation in the Petri dish. https://www.gesundheitsindustrie-bw.de/en/article/news/hela-a-human-bauplan-in-the-petri-dish
Article - 19/11/2012 Biopharm GmbH: growth factors for use in regenerative medicine With more than 26 years’ experience in the field of orthopaedics, dermatology and personalised medicine, the Heidelberg-based biotechnology company Biopharm GmbH is firmly established in the regenerative medicine market. Based on its proprietary growth factor technology platform, Biopharm develops innovative methods for the treatment of bone and cartilage damage and improvement of the wound healing process.https://www.gesundheitsindustrie-bw.de/en/article/news/biopharm-gmbh-growth-factors-for-use-in-regenerative-medicine
Article - 19/11/2012 SYMBIOSIS - The Analytical Company SYMBIOSIS, the new business unit of Heidelberg-based Biopharm GmbH, offers a wide range of analytical services, including tests, detection methods and methodological innovations related to the development of classical pharmaceuticals and biopharmaceuticals. SYMBIOSIS is a GMP- and GLP-certified provider of analytical services with long-standing experience and know-how that combines high-quality, state-of-the-art methods and solutions for its life…https://www.gesundheitsindustrie-bw.de/en/article/news/symbiosis-the-analytical-company
Press release - 16/10/2012 Merck Serono Launches € 1 Million Research Grant for Multiple Sclerosis Innovation Merck Serono, a division of Merck, Darmstadt, Germany, announced on 10th Oktober 2012 during the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress in Lyon, France, that the company has initiated a new global research award to improve understanding of multiple sclerosis for the ultimate benefit of patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/merck-serono-launches-1-million-research-grant-for-multiple-sclerosis-innovation
Press release - 03/08/2012 Rentschler and MHH sign licensing agreement for a gene therapy vector system The Hannover Medical School (MHH) and Rentschler Biotechnologie GmbH have signed a licensing agreement for the commercialization of a vector system for gene therapy that promises significant therapeutic and economic advantages over conventional technologies. Rentschler, an experienced specialist in the development of cell culture-based manufacturing processes and the production of relevant biopharmaceuticals, attains the right to develop…https://www.gesundheitsindustrie-bw.de/en/article/press-release/rentschler-and-mhh-sign-licensing-agreement-for-a-gene-therapy-vector-system
Article - 16/07/2012 Laupheim to become an international forum for biomanufacturing The 2nd Laupheimer Zelltage conference organized by Rentschler Biotechnologie GmbH in Laupheim on 11th and 12th June 2012 focused on “Bioprocess light”. Twelve experts from applied research institutions and biotech companies from Germany and abroad provided the 200 or so guests with information on how modern bioproduction methods can be made simpler, more robust, cheaper, more reliable and hence more competitive.https://www.gesundheitsindustrie-bw.de/en/article/news/laupheim-to-become-an-international-forum-for-biomanufacturing
Press release - 23/05/2012 GlaxoSmithKline to fully acquire Cellzome for 99 million U.S. dollar GlaxoSmithKline plc (GSK) announced that it has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99 million) in cash. Cellzome, a privately owned company with laboratories in Cambridge, UK, and Heidelberg, Germany, will become part of GSK’s R&D organisation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/glaxosmithkline-to-fully-acquire-cellzome-for-99-million-u-s-dollar
Article - 16/04/2012 Pharma 2.0: towards paperless production Before electronic solutions existed lorries were needed to ship new drug applications which often comprised 500000 or so pages. Thanks to IT this is no longer necessary. IT-based procedures and solutions are playing an increasing role in all areas of the pharmaceutical industry. Markus Roemer CEO of Ravensburg-based comes compliance services supports companies in implementing legal guidelines in this area. In the following interview Roemer talks…https://www.gesundheitsindustrie-bw.de/en/article/news/pharma-2-0-towards-paperless-production
Article - 19/03/2012 Protein aggregation: when proximity becomes dangerous The aggregation of proteins in the human body might have severe medical consequences, as is the case with Alzheimer’s disease, for example. A less known fact is that the biopharmaceutical industry is also faced with the biological phenomenon of protein aggregation and is working on preventive measures. https://www.gesundheitsindustrie-bw.de/en/article/news/protein-aggregation-when-proximity-becomes-dangerous
Article - 19/03/2012 Soil bacteria to produce new antibiotics An ever-growing number of genomes of soil bacteria of the genus Streptomyces are being sequenced. Using a method known as “genome mining”, researchers at the University of Tübingen are working on the identification of gene clusters that have the potential to be used in industrial biotechnology for the production of new antibiotics and other pharmaceutically active substances. To achieve this, the biosynthesis gene clusters are integrated into…https://www.gesundheitsindustrie-bw.de/en/article/news/soil-bacteria-to-produce-new-antibiotics